Pricing Log in Create free account

Polaryx Therapeutics, Inc. (PLYX) vs Rallybio Corporation (RLYB)

Polaryx Therapeutics, Inc. and Rallybio Corporation are both Biotechnology companies. Polaryx Therapeutics, Inc. and Rallybio Corporation are of similar size ($89.7M and $85.6M). Polaryx Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Rallybio Corporation trades at 3.3×. Across the 9 metrics below, Rallybio Corporation leads on 7 and Polaryx Therapeutics, Inc. on 2.

Valuation

Metric PLYX RLYB Biotechnology median
P/E n/m 3.35 10.26
P/S n/m 104.84 9.18
P/B 7.94 0.97 2.05
Price to free cash flow n/m 2.91 24.81
EV/EBITDA n/m 0.03 0.65
EV/Sales n/m (0.86) 8.98
Earnings yield (12.03%) 29.87% (34.89%)
Free cash flow yield (9.48%) 34.41% (24.52%)

Profitability

Metric PLYX RLYB Biotechnology median
Gross margin — 100.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 0.00% 34.52% (50.12%)
Return on assets (169.05%) 32.85% (45.60%)
Return on invested capital 0.00% (944.36%) 0.00%

Growth

Metric PLYX RLYB Biotechnology median
Revenue growth (TTM) — 1.18% 6.26%
EPS growth (last fiscal year) 77.72% 85.06% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric PLYX RLYB Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 13.53 28.87 4.89
Net debt to EBITDA 0.66 1.63 1.01

Dividend

Metric PLYX RLYB Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric PLYX RLYB Biotechnology median
Market cap 89.72m 85.61m 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack